ReGARDD (Regulatory Guidance for Academic Research of Drugs and Devices): The evolution of a collaborative regional CTSA-funded forum and website for regulatory support

Availability of trained professionals to assist researchers navigating regulatory pathways for new drug and device development is limited within academic institutions. We created ReGARDD (Regulatory Guidance for Academic Research of Drugs and Devices), a regional forum initially involving regulatory...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical and translational science 2021-01, Vol.5 (1), p.e82-e82, Article e82
Main Authors: Brownley, Kimberly A, Rape, Marie, Wood, Amanda, Dave, Gaurav, Henderson, Chad, Severynse-Stevens, Diana, Zmuda, Mike, Earp, Diane, Moody, Carmella, Kelly-Pumarol, Issis, Andrews, Joseph, Foss, Kristen M, Fraser, Stephanie, Segear, Erika, Parrish, Amanda B
Format: Article
Language:English
Subjects:
Annual reports
Best practice
Collaboration
Coronaviruses
Corporate sponsorship
COVID-19
CTSA
Decision trees
Education
Educational materials
FDA
Federal regulation
Gene therapy
Intellectual property
investigational device
investigational drug
Medical device industry
Medical equipment
Medical research
regulatory affairs
Researchers
Special Communications
Training
Websites
Workshops
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Availability of trained professionals to assist researchers navigating regulatory pathways for new drug and device development is limited within academic institutions. We created ReGARDD (Regulatory Guidance for Academic Research of Drugs and Devices), a regional forum initially involving regulatory professionals from four Clinical and Translational Science Award (CTSA)-funded institutions, to build and capitalize on local expertise and to develop a regulatory guidance website geared toward academic researchers. Since 2015, members organized 15 forums covering topics such as FDA premarket submissions, gene therapy, and intellectual property for devices and therapeutics. Through user feedback, targeted surveys, and ongoing iterative processes, we refined and maintained a shared regulatory website, which reached 6000+ users in 2019. Website updates improved navigation to drug versus device topic areas, provided new educational content and videos to address commonly asked questions, and created a portal for posting upcoming training opportunities. Survey respondents rated the website favorably and endorsed expanding ReGARDD as a centralized resource. ReGARDD strengthened the regional regulatory workforce, increased regulatory efficiency, and promulgated best organizational and operational practices. Broad-scale deployment of the ReGARDD model across the CTSA consortium may facilitate the creation of a network of regional forums and reduce gaps in access to regulatory support.
ISSN:2059-8661
2059-8661
DOI:10.1017/cts.2021.3